On Dec 22, 2021, the US Food and Drug Administration (FDA) issued an emergency use
authorisation for Pfizer's COVID-19 antiviral, Paxlovid. Trial results released by the …

Background Functional impairment of interferon, a natural antiviral component of the
immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to …

report a randomised trial of remdesivir (200 mg on day 1 followed by 100 mg on days 2–10,
in single daily infusions) versus placebo for adults with severe coronavirus disease 2019 …

Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

BACKGROUND: Although several therapeutic agents have been evaluated for the treatment
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …

Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro
and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We …

To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with
COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with …

The global COVID-19 pandemic is currently underway. To date, there are about 1.49 million
dead and 64.5 million people infected [1]. In this period of global pandemic, several …

Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

Summary Background The Solidarity trial among COVID-19 inpatients has previously
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …